• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

0
  • by alexperjescuadmin
  • in Oncology
  • — 10 Dec, 2007
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
AudioMedica News
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-384"/>
Pierre Fenaux
Pierre Fenaux

PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.

Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
[audio:https://www.audiomedica.com/podcasting/oncology/071209_pierre_fenaux.mp3]
Share

Tags: agentashmyelodysplasticNewspatientpodcastpodcastingpresentedreportreportsriskstudysyndrome

You may also like...

  • Whole Brain Radiotherapy Does Not Benefit Patients with Brain Metastases from Lung Cancer—European Respiratory Society 2016 Congress Whole Brain Radiotherapy Does Not Benefit Patients with Brain Metastases from Lung Cancer—European Respiratory Society 2016 Congress 5 Sep, 2016
  • ASCO Audio Journal of Oncology in Advance – October 15th, 2006 ASCO Audio Journal of Oncology in Advance – October 15th, 2006 14 Oct, 2006
  • Early Lung Cancer Responds to Preoperative Nivolumab Early Lung Cancer Responds to Preoperative Nivolumab 17 Nov, 2016
  • Ayal Aizer Low risk prostate cancer: less treatment means lower cost, and better patient outcomes 16 Mar, 2013

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Live Report from ASH:
    Interleukin-2 For Acute Myeloid Leukemia In First Remission?
  • Next story Live Report from ASH:
    Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • New Front Line Standard for Older Patients with…
    • Head and Neck Cancer Therapy De-Escalation: A…
    • Brachytherapy “Excellent” After Breast…
  • Home
  • Oncology
  • Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.